RTT

Purdue Pharma’s Avrio Health Launches Betadine® Antiseptic Oral Rinse for Professional Use

Retrieved on: 
Monday, February 8, 2021
Medical Supplies, Health, Surgery, Other Health, Dental, Pharmaceutical, Health, Chemistry, Physical sciences, RTT, Dosage forms, Antiseptics, Disinfectants, Polyvinylpyrrolidone, Mouthwash, Topical medication, Povidone-iodine, Iodine, Betadine, Avrio Health L.P., Purdue Pharma L.P.

Avrio Health L.P. (Avrio), a subsidiary of Purdue Pharma L.P. (Purdue), today announced the launch of new Betadine Antiseptic Oral Rinse (active ingredient 0.5% povidone-iodine, or PVP-I), an oral antiseptic pre-procedural rinse.

Key Points: 
  • Avrio Health L.P. (Avrio), a subsidiary of Purdue Pharma L.P. (Purdue), today announced the launch of new Betadine Antiseptic Oral Rinse (active ingredient 0.5% povidone-iodine, or PVP-I), an oral antiseptic pre-procedural rinse.
  • Betadine antiseptic products have been used in the hospital and outpatient settings for their antiseptic (antimicrobial) properties for more than 50 years.
  • Betadine Antiseptic Oral Rinse should be administered by professionals and used orally (do not swallow) in preparation of the oral mucosa prior to injection, dental surgery, or tooth extraction.
  • Betadine Topical Antiseptic products currently available in the U.S. are for external use only and should not be gargled or swallowed.

United States Head & Neck Cancers Market Report: Epidemiology, Valuations And Forecast, Drugs Sales and Competitive Landscape 2017-2026 - ResearchAndMarkets.com

Retrieved on: 
Monday, February 8, 2021
Health, Oncology, RTT, Otorhinolaryngology, Head and neck cancer, Cancer, ATM serine/threonine kinase

The "US Head & Neck Cancers Market and Competitive Landscape - 2021" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "US Head & Neck Cancers Market and Competitive Landscape - 2021" report has been added to ResearchAndMarkets.com's offering.
  • The latest research US Head & Neck Cancers Market and Competitive Landscape Highlights - 2021, provides comprehensive insights into Head & Neck Cancers pipeline products, Head & Neck Cancers epidemiology, Head & Neck Cancers market valuations and forecast, Head & Neck Cancers drugs sales and competitive landscape in the US.
  • Head & Neck Cancers pipeline: Find out the products in clinical trials for the treatment of Head & Neck Cancers by development phase 3, phase 2, and phase 1, by pharmacological class and companies developing the products
    Head & Neck Cancers epidemiology: Find out the number of patients diagnosed (prevalence) with Head & Neck Cancers in the US
    Head & Neck Cancers drugs: Identify key products marketed and prescribed for Head & Neck Cancers in the US, including trade name, molecule name, and company
    Head & Neck Cancers drugs sales: Find out the sales revenues of Head & Neck Cancers drugs in the US
    Head & Neck Cancers market valuations: Find out the market size for Head & Neck Cancers drugs in 2019 in the US.
  • Find out how the market advanced from 2017 and forecast to 2026
    Head & Neck Cancers drugs market share: Find out the market shares for key Head & Neck Cancers drugs in the US
    Evaluate commercial market opportunity assessment, positioning, and segmentation for Head & Neck Cancers products
    View source version on businesswire.com: https://www.businesswire.com/news/home/20210208005471/en/

United States Urinary Tract Infections Market Report 2021: Epidemiology, Valuations And Forecast, Drugs Sales and Competitive Landscape 2017-2026 - ResearchAndMarkets.com

Retrieved on: 
Monday, February 8, 2021
Infectious diseases, Health, Clinical trials, Medical specialties, Infectious diseases, Medicine, Urinary tract infection, Clinical medicine, RTT, Fluoroquinolone antibiotics

The "US Urinary Tract Infections Market and Competitive Landscape - 2021" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "US Urinary Tract Infections Market and Competitive Landscape - 2021" report has been added to ResearchAndMarkets.com's offering.
  • US Urinary Tract Infections Market and Competitive Landscape Highlights - 2021, provides comprehensive insights into Urinary Tract Infections pipeline products, Urinary Tract Infections epidemiology, Urinary Tract Infections market valuations and forecast, Urinary Tract Infections drugs sales and competitive landscape in the US.
  • Urinary Tract Infections pipeline: Find out the products in clinical trials for the treatment of Urinary Tract Infections by development phase 3, phase 2, and phase 1, by pharmacological class and companies developing the products
    Urinary Tract Infections drugs: Identify key products marketed and prescribed for Urinary Tract Infections in the US, including trade name, molecule name, and company
    Urinary Tract Infections drugs sales: Find out the sales revenues of Urinary Tract Infections drugs in the US
    Urinary Tract Infections market valuations: Find out the market size for Urinary Tract Infections drugs in 2019 in the US.
  • Find out how the market advanced from 2017 and forecast to 2026
    Urinary Tract Infections drugs market share: Find out the market shares for key Urinary Tract Infections drugs in the US
    Evaluate commercial market opportunity assessment, positioning, and segmentation for Urinary Tract Infections products
    View source version on businesswire.com: https://www.businesswire.com/news/home/20210208005468/en/

Amid Vaccination Roll Out, Government, Education, and Enterprise Verticals Embrace Everbridge’s Vaccine Distribution Software

Retrieved on: 
Monday, February 8, 2021
Technology, Medical Supplies, Infectious diseases, Security, Software, Biotechnology, Health, Pharmaceutical, Data management, Vaccines, RTT, Medical specialties, Vaccination, Medicine, Biotechnology, Vaccine, Life sciences, HPV vaccine

Utilizing Everbridges vaccine distribution software, more than 190,000 West Virginians have signed up to be vaccinated, with 81% of long-term care facility residents now registered.

Key Points: 
  • Utilizing Everbridges vaccine distribution software, more than 190,000 West Virginians have signed up to be vaccinated, with 81% of long-term care facility residents now registered.
  • View the full release here: https://www.businesswire.com/news/home/20210208005215/en/
    In a conversation with the U.S. Chamber of Commerce Foundation, Governor Justice shared his secrets to vaccination success .
  • Within five days of launch, we have pre-registered more than 100,000 citizens who want to receive the vaccine when doses are made available.
  • The offering also provides governments with a single, unified platform to expedite vaccine coordination, communication and distribution for residents.

BioVentrix Receives 2021 NUB Status 1 Reimbursement Renewal in Germany for the Revivent TC TransCatheter Ventricular Enhancement System

Retrieved on: 
Monday, February 8, 2021
Surgery, Medical devices, Health, Clinical trials, Cardiology, Circulatory system, Medical devices, Interventional cardiology, Cardiology, Medicine, RTT, Heart, Organs, Revivent

LIVE Therapy uses the Revivent TC System to exclude scar tissue on the left ventricle that has occurred from a heart attack so the healthy portion of the heart can operate more efficiently.

Key Points: 
  • LIVE Therapy uses the Revivent TC System to exclude scar tissue on the left ventricle that has occurred from a heart attack so the healthy portion of the heart can operate more efficiently.
  • The Revivent TC System has received the CE Mark and is commercially available in Europe, where adoption is expanding.
  • In the U.S., the company is currently enrolling patients in its pivotal trial of the Revivent TC System, the ALIVE Trial.
  • Less invasive ventricular reconstruction for ischemic heart failure.

Cue Biopharma Initiates Patient Dosing in Phase 1 Study of CUE-101 in Combination with KEYTRUDA® (pembrolizumab) as First-line Treatment for HPV+ Recurrent/Metastatic Head and Neck Cancer

Retrieved on: 
Monday, February 8, 2021
Cancer, Neoplasms, Clinical medicine, RTT, Antineoplastic drugs, Breakthrough therapy, Head and neck cancer, Otorhinolaryngology, Pembrolizumab, Head and neck squamous-cell carcinoma, Human papillomavirus infection, Papilloma

CUE-101 is being evaluated in combination with KEYTRUDA as first-line treatment for human papilloma virus positive recurrent/metastatic head and neck squamous cell carcinoma (HPV+ R/M HNSCC).

Key Points: 
  • CUE-101 is being evaluated in combination with KEYTRUDA as first-line treatment for human papilloma virus positive recurrent/metastatic head and neck squamous cell carcinoma (HPV+ R/M HNSCC).
  • We are very pleased to have initiated our combination trial of CUE-101 with KEYTRUDA, said Ken Pienta, M.D, acting chief medical officer of Cue Biopharma.
  • These data taken together support our belief that the combination of CUE-101 with KEYTRUDA has the potential to enhance anti-tumor activity and prolong patient survival.
  • This Phase 1 dose escalation combination trial ( NCT03978689 ) is being conducted in parallel at the same clinics that are conducting the ongoing Phase 1 monotherapy study of CUE-101.

GeneSight Psychotropic Test’s Combinatorial Approach Proves Better than Single-Gene Testing at Predicting Patient Outcomes and Medication Blood Levels

Retrieved on: 
Monday, February 8, 2021
Chemical compounds, RTT, Selective serotonin reuptake inhibitors, Chemistry, Organic compounds, Genomics, Pharmacogenomics, Pharmacology, Pharmacy, Escitalopram, Citalopram

SALT LAKE CITY, Feb. 08, 2021 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in genetic testing and precision medicine, announced today the peer-reviewed journal Psychiatry Research has published a new analysis showing the combinatorial approach available in the GeneSight Psychotropic test is better than single-gene testing at predicting patient outcomes and medication blood levels.

Key Points: 
  • SALT LAKE CITY, Feb. 08, 2021 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in genetic testing and precision medicine, announced today the peer-reviewed journal Psychiatry Research has published a new analysis showing the combinatorial approach available in the GeneSight Psychotropic test is better than single-gene testing at predicting patient outcomes and medication blood levels.
  • Using data from the Genomics Used to Improve DEpression Decisions (GUIDED) randomized-controlled trial, the study evaluated the ability of the combinatorial approach available in the GeneSight Psychotropic test to predict patient outcomes and medication blood levels compared to Clinical Pharmacogenetics Implementation Consortium(CPIC) single-gene recommendations.
  • Medication Blood Levels The analysis of the combinatorial pharmacogenomic test and single-gene guidelines showed the predictive ability of the GeneSight combinatorial approach was better.
  • This is the second study evaluating the combinatorial approach of the GeneSight test to be published inPsychiatry Research.The earlier study, published in May 2020, demonstrated the combinatorial approach available in the GeneSight Psychotropic test was better at predicting citalopram and escitalopram blood concentrations when compared to single-gene testing.

Bayer and Orion Expand Development Program for NUBEQA® (darolutamide) in Prostate Cancer

Retrieved on: 
Monday, February 8, 2021
Pharmaceutical, Health, Oncology, Chemical compounds, Organic compounds, Hormones, Prostate cancer, Nonsteroidal antiandrogens, Progonadotropins, RTT, Bicalutamide, Androgen deprivation therapy, the ARANOTE Trial, NUBEQA® (darolutamide)1, Metastatic Hormone-Sensitive Prostate Cancer, Oncology at Bayer, Bayer

Bayer and Orion Corporation are expanding the global clinical development program for the oral androgen receptor inhibitor (ARi) NUBEQA (darolutamide) in prostate cancer.

Key Points: 
  • Bayer and Orion Corporation are expanding the global clinical development program for the oral androgen receptor inhibitor (ARi) NUBEQA (darolutamide) in prostate cancer.
  • NUBEQA has already shown in men with non-metastatic castration-resistant prostate cancer (nmCRPC) that it extends metastasis-free and overall survival, said Scott Z.
  • NUBEQA (darolutamide) is an androgen receptor inhibitor indicated for the treatment of patients with non-metastatic castration-resistant prostate cancer.
  • Effect of Other Drugs on NUBEQA Combined P-gp and strong or moderate CYP3A4 inducers decrease NUBEQA exposure, which may decrease NUBEQA activity.

Gemini Therapeutics Debuts as Publicly Traded Precision Medicine Company Focused on Age-Related Macular Degeneration

Retrieved on: 
Monday, February 8, 2021
Health, Genetics, General Health, Clinical trials, Pharmaceutical, Optical, Biotechnology, Macular degeneration, RTT, Senescence, Organ systems, Stem cells, Biology, Life sciences, Astellas Institute for Regenerative Medicine, GEM103, Dry Age-Related Macular Degeneration (AMD), Gemini Therapeutics

Gemini Therapeutics, a clinical stage precision medicine company developing innovative treatments for genetically defined age-related macular degeneration (AMD), today announced the completion of its business combination with FS Development Corp. (Nasdaq: FSDC), a special purpose acquisition company (SPAC) sponsored by Foresite Capital.

Key Points: 
  • Gemini Therapeutics, a clinical stage precision medicine company developing innovative treatments for genetically defined age-related macular degeneration (AMD), today announced the completion of its business combination with FS Development Corp. (Nasdaq: FSDC), a special purpose acquisition company (SPAC) sponsored by Foresite Capital.
  • Gemini Therapeutics, Inc., the resulting combined company, will commence trading its shares today on the Nasdaq Global Market under the symbol GMTX.
  • Gemini Therapeutics management team will continue to be led by Chief Executive Officer Jason Meyenburg.
  • Gemini Therapeutics is a clinical stage precision medicine company developing novel therapeutic compounds to treat genetically defined age-related macular degeneration (AMD).

LENSAR to Present at Two Upcoming Investor Conferences

Retrieved on: 
Monday, February 8, 2021
Optical, Health, Surgery, Medical devices, Optics, Light, RTT, Vision, Senses, Ophthalmology, Blindness, Cataract, Eye, Laser, Astigmatism

LENSAR, Inc. (Nasdaq: LNSR) (LENSAR or the Company), a global medical technology company focused on advanced femtosecond laser surgical solutions for the treatment of cataracts, today announced that Nick Curtis, Chief Executive Officer, will present at two upcoming investor conferences:

Key Points: 
  • LENSAR, Inc. (Nasdaq: LNSR) (LENSAR or the Company), a global medical technology company focused on advanced femtosecond laser surgical solutions for the treatment of cataracts, today announced that Nick Curtis, Chief Executive Officer, will present at two upcoming investor conferences:
    Live webcasts of the presentations can be accessed through the Investors section of the Company's website at https://ir.lensar.com .
  • A replay of the webcasts will be available on the LENSAR website for two weeks following the respective conferences.
  • LENSAR is a commercial-stage medical device company focused on designing, developing and marketing an advanced femtosecond laser system for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism.
  • Its LENSAR Laser System incorporates a range of proprietary technologies designed to assist the surgeon in obtaining better visual outcomes, efficiency and reproducibility by providing advanced imaging, simplified procedure planning, efficient design and precision.